Business of the House

Debate between Lord Lansley and Jonathan Evans

Thursday 21st November 2013 Commons Chamber

[Mr Lansley]

I heard the Prime Minister respond to that question and provide the accurate figure, which was that something approaching 1% of Sure Start children’s centres have closed—nothing like the figure the hon. Gentleman refers to. The Prime Minister also pointed out that financial support for early intervention is rising in this financial year from £2.3 billion to £2.5 billion.

[Jonathan Evans (Cardiff North) (Con)]

May we have an early debate on the future of mutuals and co-operatives, so that those of us who have consistently supported the mutual concept have the opportunity to argue the case on behalf of well run, properly regulated and non-political mutuals and co-operatives, and to demonstrate the contribution that they have made to this country?

[Mr Lansley]

I cannot promise a debate immediately, but I completely understand the point that my hon. Friend rightly makes. The failings that have been evident in the way in which the Co-operative bank was run and the implications of that are a matter of the greatest disappointment to many of us. I personally share with my hon. Friend a sense that we do not want that to undermine the commitment to mutuals and co-operatives as a form of organisation for businesses. They have tremendous potential—as yet unrealised potential in many cases—for ensuring that businesses are very successful in the long term because they engage staff successfully and enable staff as well as customers of an organisation to feel that they have a stake in its long-term future.

Contaminated Blood

Debate between Lord Lansley and Jonathan Evans

Monday 10th January 2011 Commons Chamber

[Mr Lansley]

I am grateful to the hon. Lady and I entirely endorse her opening and closing remarks paying tribute to all the patient groups. My hon. Friend the Under-Secretary of State for Health has met many of those groups and individuals, and I know that she would heartily endorse what the hon. Lady said about how they have brought these issues time and again to the forefront of attention in the House and the other place. I do not want to underestimate the many in the House and the other place who responded to that and did so very well by bringing these cases forward. I hope that they will see in today’s statement a proper response.

We do not know whether there will ever be a similar case. I hope we can avoid it—it would be much better to avoid it—but if we were ever in a situation where such a consequence flowed from the NHS seeking to do its best to treat patients but such harm nevertheless occurred, I hope we would recognise that, be able to identify it and not allow decades to pass before proper recognition took place.

That brings me to the hon. Lady’s substantive point, which is the relationship between what we are doing and the compensation provided in the Republic of Ireland. As we explained in October, we do not regard these as comparable cases. In the Republic of Ireland, mistakes were made by the Irish Blood Transfusion Service which led to a recognition of liability, leading to a determination of compensation. In this country we are not providing compensation. We are recognising the harm that occurred, notwithstanding the fact that the NHS at the time sought to provide the treatment that it thought was in the best interests of patients.

That harm occurred. As an ex gratia payment and in recognition of the harm that occurred and the distress that followed, we have sought to ensure that there is proper support, financial and otherwise, for the victims and their families. I hope that by getting rid of the anomalies and recognising—in particular, through the work of the clinical expert group—the impact on those with hepatitis C, we are giving the support that those who were damaged should expect.

[Jonathan Evans (Cardiff North) (Con)]

Although I welcome my right hon. Friend’s statement, I should point out that Lord Archer recommended that there should be compensation along the Irish lines. That is a little of the context of what has taken place.

I take the opportunity of congratulating the Under-Secretary of State for Health, my hon. Friend the Member for Guildford (Anne Milton) on all the work that she has done on the matter, which I know has been welcomed across the House.

May I ask my right hon. Friend about the position in Wales? I was a little taken aback by the fact that he said that he intends to speak to fellow Ministers in Wales. I have a statement from the Welsh Minister indicating that as far as she is concerned, these issues come next to be considered by her in 2014, which was the previous agreement with the Department of Health. Many of my constituents will want to know what discussions have so far taken place and whether the arrangements will be replicated in the Principality.

[Mr Lansley]

The Under-Secretary will have heard what my hon. Friend said. I am grateful for it, too.

I am speaking on behalf of England in this respect. As the Department of Health, we administer the payments system. We had to reach the decisions and we have done so. We always intended to do so as rapidly as we could for England, but as I explained in my statement, these decisions have yet to be made by the devolved Administrations. It is reasonable for them to see the review report that I am publishing today, not least the clinical expert review that goes with it, in order for them to make their own decisions. Those are decisions that they must make, but if they wished us to continue to administer the system on the same basis across the United Kingdom, we would be happy to do so.